The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarker study of BND-22 in combination with cemiplimab in solid tumors.
 
Mohamed Derbala
No Relationships to Disclose
 
Cara Haymaker
Stock and Other Ownership Interests - Briacell
Consulting or Advisory Role - Regeneron
Research Funding - ARTIDIS (Inst); AstraZeneca/MedImmune (Inst); Avenge Bio (Inst); BTG (Inst); EMD Serono/Merck (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); KSQ Therapeutics (Inst); Nanobiotix (Inst); Novartis (Inst); Obsidian Therapeutics (Inst); Sanofi (Inst); Summit Therapeutics (Inst); Takeda (Inst); Theolytics (Inst); Yingli Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Patent Appl No. 62/977, 672 (Inst)
 
Van Morris
Consulting or Advisory Role - Abbvie; BioNTech SE; Bristol-Myers Squibb/Celgene; Exelixis; GlaxoSmithKline; Incyte; Pfizer
Research Funding - Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst)
 
Milind Javle
Honoraria - AstraZeneca/MedImmune; EMD Serono/Merck; Incyte; Merck; QED Therapeutics; TransThera Biosciences
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Jeffrey How
Research Funding - MacroGenics; Merck
Travel, Accommodations, Expenses - Gilead Sciences
 
Ann-Marie Cimo
No Relationships to Disclose
 
Serdar Gurses
No Relationships to Disclose
 
Bettzy Stephen
No Relationships to Disclose
 
Tin-Yun Tang
Stock and Other Ownership Interests - Editas Medicine; Invitae; Uniqure
 
Stephane Champiat
Stock and Other Ownership Interests - Avacta Life Sciences
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai Europe; Fresenius Kabi; Genmab; Janssen; Merck KGaA; Merck Serono; MSD; Novartis; Roche; SERVIER; Takeda
Consulting or Advisory Role - Alderaan Biotechnology; Amgen; AstraZeneca; Avacta Life Sciences; Bayer; BeiGene; BioCodex; BioNTech SE; Boehringer Ingelheim; Celanese; Compugen; Domain Therapeutics; Ellipses Pharma; GE Healthcare; Genmab; Guardant Health; Immunicom; Ipsen; Mariana Oncology; Mima Health; Nanobiotix; NextCure; Oncovita; PharmaMar; Pierre Fabre; Replimune; Seagen; Takeda; Tatum Bioscience; Tollys; UltraHuman8
Research Funding - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Bolt Biotherapeutics; Centessa Pharmaceuticals; Cytovation; Eisai/H3 Biomedicine; Exelixis; GlaxoSmithKline; ImCheck therapeutics; Immunocore; Kumquat Biosciences; Marengo Therapeutics; Molecular Partners; MSD; OncoC4; OSE Immunotherapeutics; Owkin; Pheast Therapeutics; Pierre Fabre; Replimune; Roche/Genentech; Sanofi; Seagen; Sotio; Transgene; Trutino Biosciences; Veracyte (Inst); VIR Biotechnology
Patents, Royalties, Other Intellectual Property - T-cell immunogens derived from anti-viral proteins and methods of using same WO2010039223A2
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GE Healthcare; Merck; MSD; OSE Immunotherapeutics; Roche; Sotio
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Amgen; BioHybrid Solutions; Bridgebio Pharma; Bristol-Myers Squibb; Debiopharm Group; Ellipses Pharma; iOnctura; Merus; Monte Rosa Therapeutics
Research Funding - 280Bio (Inst); AstraZenneca (Inst); Blueprint Medicines (Inst); Bristol Myers Squibb; Hummingbird (Inst); Merck Sharp & Dohme (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst)
Travel, Accommodations, Expenses - American Society of Medical Oncology; Dava Oncology; ESMO; STOP Cancer
Other Relationship - AstraZeneca; Boxer Capital; EcoR1 Capital; Guidepoint Pharmacy; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Timothy Yap
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - 858 Therapeutics; Abbvie; Acrivon Therapeutics; Adagene; Aduro Biotech; Almac Group; Amphista Therapeutics; Artios; Astex Pharmaceuticals; AstraZeneca; Athenahealth; Atrin Pharmaceuticals; Avenzo; Avoro Capital Advisors; Axiom Biotechnologies; Baptist Health; Bayer; BeiGene; BioCity Pharma; Blueprint Medicines; Boxer; Bristol-Myers Squibb; C4 Therapeutics; Calithera Biosciences; Cancer Research UK; Carrick Therapeutics; Circle Pharma; Clovis Oncology; Cybrexa Therapeutics; Daiichi Sankyo; Dark Blue Therapeutics; Diffusion Pharmaceuticals; Duke Street Bio; EcoR1 Capital; Ellipses Pharma; EMD Serono; Entos; F-Star; Genesis Therapeutics; Genmab; Gerson Lehrman Group; GlaxoSmithKline; Glenmark; Globe Life Science; Guidepoint Global; Gustave Roussy Cancer Center; I-Mab; IDEAYA Biosciences; Idience; Ignyta; ImmuneSensor Therapeutics; IMPAC Medical Systems; Intellisphere; Janssen; Kyn therapeutics; MEI Pharma; Merck; Mereo BioPharma; Merit, Inc.; Monte Rosa Therapeutics; Natera; Nested Therapeutics; Nexys Therapeutics; Nimbus Therapeutics; Novocure; Odyssey Therapeutics; OncoSec; Ono Pharmaceutical; Onxeo; Oregon Health & Science University (OHSU); PanAngium Therapeutics; Pegascy; PER; Pfizer; Piper Sandler; Pliant; ProLynx; Radiopharma Theranostics; Repare Therapeutics; resTORbio; Roche; Ryvu Therapeutics; SAKK; Sanofi; Schrodinger; SERVIER; Synnovation; Synthis Therapeutics; Tango Therapeutics; TCG Crossover; TD2; Terns Pharmaceuticals; Terremoto Biosciences; Tessellate Bio; Theragnostics; Thryv Therapeutics; Tolremo; Tome; Trevarx Biomedical; Varian Medical Systems; Veeva; Versant Health; Vibliome Therapeutics; Voronoi Health Analytics; Xinthera; Zai Lab; ZielBio
Research Funding - Acrivon Therapeutics; Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); BMS (Inst); Boundless Bio; Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Cyteir (Inst); Department of Defense; EMD Serono (Inst); F-Star (Inst); Forbius (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Haihe Biopharma (Inst); IDEAYA Biosciences; ImmuneSensor Therapeutics (Inst); InSilico Medicine; Ionis Pharmaceuticals (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); KSQ Therapeutics (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); NIH/NCI; Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Tango Therapeutics; Tesaro (Inst); V Foundation; Vivace Therapeutics (Inst); Zenith Epigenetics (Inst)
 
Ecaterina Dumbrava
Consulting or Advisory Role - Bolt Biotherapeutics; Fate Therapeutics; Mersana; PMV Pharma; Summit Therapeutics
Speakers' Bureau - PMV Pharma
Research Funding - A2A Pharmaceuticals (Inst); Aileron Therapeutics (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Compugen (Inst); Dragonfly Therapeutics (Inst); Fate Therapeutics (Inst); Genentech (Inst); Immunocore (Inst); Immunomedics/Gilead (Inst); Mereo BioPharma 5 (Inst); Mersana (Inst); ModeX Therapeutics (Inst); Pfizer (Inst); PMV Pharma (Inst); Poseida (Inst); Rain Therapeutics (Inst); Sanofi (Inst); Sotio (Inst); Triumvira Immunologics, Inc (Inst); Volastra Therapeutics (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Rain Oncology; Triumvira Immunologics, Inc
 
Sarina Piha-Paul
Consulting or Advisory Role - Mitsubishi Tanabe Pharma America (MTPA) Inc.
Research Funding - Alkermes (Inst); Aminex (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Cancer Prevention Research Institute of Texas (CPRIT) (Inst); Chugai Pharma (Inst); Clinical and Translational Science Award Grant (CTSA) 1UM1TR0045906 (Inst); Cyclacel (Inst); Daichi Sanko (Inst); Day One Biopharmaceuticals (Inst); ENB Therapeutics (Inst); Epigenetix (Inst); Genmab (Inst); Gilead Sciences (Inst); Immunity Bio, Inc. (Inst); Immunome, Inc. (Inst); Immunomedics (Inst); Incyte (Inst); Innovent Biologics (Inst); Jazz Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Juangsu Simcere Pharmaceutical Co., Ltd. (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp and Dohme Corp. (Inst); Mitsubishi Tanabe Pharma America (MTPA) Inc. (Inst); Nectin Therapeutics (Inst); Nested Therapeutics (Inst); NIH/NCI (Inst); NRG Oncology (Inst); Nurix (Inst); OncoNano Inc (Inst); Pfizer (Inst); Phanes Therapeutics (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Purinomia (Inst); Pyxis (Inst); Replimune (Inst); Solve Therapeutics, Inc. (Inst); Strand Therapeutics, Inc. (Inst); Theradex (Inst); Toragen Therapeutics, Inc. (Inst); TransThera Biosciences (Inst); ViroMissile, Inc. (Inst); ZielBio (Inst)
 
Apostolia Tsimberidou
Consulting or Advisory Role - Avstera; BrYet; Integra PrecisionQ; Macrogenics; Nex-I; OBI Pharma (Inst)
Research Funding - Abbvie (Inst); Agenus (Inst); Anaveon (Inst); IMMATICS (Inst); Macrogenics (Inst); Novocure (Inst); OBI Pharma (Inst); Orionis (Inst); Parker Institute for Cancer Immunotherapy (Inst); Tachyon (Inst); Tempus (Inst); Vividion Therapeutics (Inst)
 
Siqing Fu
Research Funding - Abbisko (Inst); Antengene (Inst); BeiGene (Inst); BeyondSpring Pharmaceuticals (Inst); Biotheus (Inst); Boehringer Ingelheim (Inst); Clinical and Translational Science Award Grant (CTSA) 1UM1TR0045906 (Inst); Coherent Biopharma (Inst); CPRIT Precision Oncology Decision Support Core (RP150535) (Inst); Crossignal (Inst); CUE Biopharma (Inst); DEKA Biosciences (Inst); Exelis (Inst); Exelis (Inst); Fore Biotherapeutics (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); Jazz Pharmaceuticals (Inst); K-Group Beta (Inst); Lantern Pharma (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); MediLink Therapeutics (Inst); Millennium (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Nykode Therapeutics (Inst); Parexel International, LLC (Inst); PharmaMar (Inst); Pionyr (Inst); PureTech (Inst); Qurgen Inc. (Inst); Sellas Life Sciences (Inst); Shanghai Huaota Biopharmaceutical (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Tigermed Group (Inst); TransCode Therapeutics, Inc. (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Virogin Biotech (Inst)
 
David Hong
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - Breakthrough Bio; crossbridge Bio; MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - Abbvie; Acuta Capital Partners; Alphasights; Amgen; BeiGene; Blueprint Medicines; Boxer Capital; Boxer Capital; Clearview Oncology; COR2ed; EcoR1 Capital; Erasca, Inc; Gerson Lehrman Group; Guidepoint Pharmacy; Immunogenesis; Kestrel Therapeutics; Medscape; Morgan Stanley; Nextech Invest; Pfizer; PharmaResearch; Revolution Medicines; Sequenom; T-Knife; WebMD
Research Funding - Abbvie (Inst); Acendo; Adaptimmune; Adlai Nortye; Alterome Therapeutics; Amgen (Inst); Arvinas; AstraZeneca; Bayer (Inst); BeiGene; BioBridge (Inst); Bristol Myers Squibb (Inst); Deciphera Pharmaceuticals Inc. (Inst); Endeavor BioMedicines; Erasca, Inc; Exelixis (Inst); Genentech; Genentech (Inst); Immunogenesis; InhibRx; KumQuat; Kura Oncology; Lilly; Merck Sharp & Dohme LLC (Inst); National Cancer Institute; Novartis; Pfizer (Inst); Quanta Therapeutics (Inst); Revolution Medicines; Roche; ST Cube; Velavagio; Verastem; VM Pharma
Travel, Accommodations, Expenses - AACR; ImmunoGenesis; Medscape; Telperian
 
Natalia Ashtamker
Employment - Biond Biologics
Leadership - Biond Biologics
Stock and Other Ownership Interests - Biond Biologics
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dava Oncology
Consulting or Advisory Role - AstraZeneca; Becton Dickinson; Biocartis; Calibr; Cybrexa Therapeutics; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Debiopharm Group; eFFECTOR Therapeutics; Elevation Oncology; Exelixis; Go Therapeutics; GT Aperion; Guardant Health; Harbinger Health; Illumen; Incyte; Jazz Pharmaceuticals; Kivu Biosciences; Lengo Therapeutics; LigaChem Biosciences; Loxo/Lilly; Menarini Group; Mersana; Molecular Templates; OnCusp Therapeutics; Protai; Ribometrix; Sanofi; Seagen; SystImmune; Tallac Therapeutics; Tempus; Theratechnologies; Vir Biotechnology; Zentalis; Zymeworks
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); PUMA Biotechnology (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Cholangiocarcinoma Foundation; Dava Oncology; ESMO; European Organisation for Research and Treatment of Cancer (EORTC); Physicans' Education Resource
 
Aung Naing
Employment - Baylor College of Medicine and Texas Children's Hospital (I); MD Anderson Cancer Center
Honoraria - AKH Inc.; American Society of Clinical Oncology; CME Outfitters; ESMO; Korean Society of Medical Oncology (KSMO); Lynx Group; Scripps Hospital; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Abbvie; Cogent Biosciences (I); CTI; CytomX Therapeutics; Deka Biosciences; Genome & Company; Immune-Onc Therapeutics; Janssen Biotech; Lynx Health; Merk Sharp & Dohme Corp; NGM Biopharmaceuticals; Nouscom; OncoSec; Pharming NV (I); PsiOxus Therapeutics; SERVIER; STCube Pharmaceuticals Inc.; The Immune Deficiency Foundation (I)
Speakers' Bureau - WebMD (I)
Research Funding - Amplimmune; Arcus Biosciences; ARMO BioSciences; Atterocor; BioNTech SE; Bristol-Myers Squibb; Calithera Biosciences; CytomX Therapeutics; EMD Serono; GV 20 Therapeutics; Healios; Immune Deficiency Foundation (I); Immune-Onc Therapeutics; Incyte; Jeffrey Modell Foundation (I); Karyopharm Therapeutics; Kymab; Lilly; MedImmune; Merck; Monopteros Therapeutics; NCI; NeoImmuneTech; Neon Therapeutics; Novartis; Pfizer; PsiOxus Therapeutics; Regeneron; Seven and Eight Biopharmaceuticals; Sotio; Surface Oncology; Takeda (I); TopAlliance BioSciences Inc
Travel, Accommodations, Expenses - ARMO BioSciences; NeoImmuneTech; NGM Biopharmaceuticals
Other Relationship - Pharming-PI for clinical trial (I)
(OPTIONAL) Uncompensated Relationships - KN Foundation USA